Clinical trial NCT01064414: An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Official title: A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Diabetes Mellitus, Type 2
Renal Insufficiency
Keywords: Canagliflozin
JNJ 28431754
Placebo
Sodium-Glucose Transporter 2
hemoglobin A1c protein, Blood Glucose
reduced kidney function, Type 2 diabetes mellitus
Lead sponsor: Janssen Research & Development, LLC
Sponsor class: INDUSTRY
First posted: 2010-02-08
Enrollment: 272
Sex: ALL
Minimum age (years): 25
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who have reduced kidney function.

Detailed description: This is a randomized (study drug assigned by chance), double blind (neither the patient or the study doctor will know the name of the assigned treatment), parallel-group, 3-arm (patients will be assigned to 1 of 3 treatment groups) multicenter study to determine the efficacy, safety, and tolerability of 2 different doses of canagliflozin (100 mg and 300 mg) compared to placebo (a pill that looks like all the other treatments but has no real medicine) in patients with type 2 diabetes mellitus (T2DM) who have renal impairment (reduced kidney function) and who are not achieving an adequate response from current therapy to control their diabetes. Canagliflozin (also referred to as JNJ-28431754) is a drug that is being tested to see if it may be useful in treating patients diagnosed with T2DM. Approximately 240 patients will participate in the study for approximately 63 to 72 weeks, depending on the length of the pretreatment phase. The study will consist of a pretreatment phase, a 52 week double blind treatment phase, and a posttreatment phase. During the pretreatment phase, screening evaluations will be performed to see if patients meet the entry criteria for the study. In addition, routine clinical procedures will be performed (physical examination, vital signs measurements, and an electrocardiogram \[ECG\]), a blood and urine sample will be collected for routine clinical laboratory tests, and all antihyperglycemic therapy taken by patients will be reviewed. Patients who meet entrance criteria for the study and who currently take a stable antihyperglycemic agent (AHA) regimen according to the local prescribing information will be eligible for inclusion in the study. Patients who meet entrance criteria for the study but who are not taking a stable AHA regimen according to the local prescribing information will enter an AHA adjustment period that may last for up to 12 weeks. Patients will receive once daily treatment with study drug in addition to their current stable diabetes regimen (eg, diet, exercise, and medication therapy). Patients will continue to take their assigned treatment for 52 weeks (includes a 26-week core double-blind treatment period and a 26-week extension double-blind treatment period). During the study, if a patient's blood sugar remains high despite treatment with study drug in combination with their other antidiabetic agents, the study physician will modify the patient's treatment. If patients take insulin and experience low blood sugar (hypoglycemia), the dose of insulin may be modified. During the study, patients will be monitored for safety by review of adverse events, results from safety laboratory tests (including chemistry, hematology, and urinalysis), ECGs, vital signs measurements, body weight, physical examinations, self-monitored blood glucose, and collection of potential hypoglycemic episodes reported by patients on diary cards. The safety of patients in this study will also be monitored by a company internal Medical Safety Review Committee (MSRC). An Independent Data Monitoring Committee (IDMC) will evaluate cardiovascular (CV) events that are reported across the entire clinical development program for canagliflozin. Patients who complete the Week 52 visit or who discontinue treatment early and are withdrawn from the study will have end-of-study evaluations performed and a follow-up telephone interview conducted by study personnel approximately 30 days (but no more than 42 days) after the last dose of study drug to collect any serious adverse events that occurred since their last study visit. The primary outcome measures in the study are to assess the effect of canagliflozin relative to placebo on hemoglobin A1c (HbA1c, a blood test used to measure the control of diabetes) after 26 weeks of treatment and to assess the safety and tolerability of canagliflozin from time of signed informed consent to study end (includes up to 30 days following the last dose of study drug). All patients will take a single-blind placebo capsule once daily for 2 weeks before randomization to double-blind study drug. After randomization, patients will take one capsule of canagliflozin (either 100 mg or 300 mg) or matching placebo orally (by mouth) with liquid once daily for 52 weeks before the first meal each day except on days when fasting or pharmacokinetic blood samples are collected in which case study drug will be taken after the visit immediately before the patient's next meal.

Eligibility criteria: Inclusion Criteria:

* Patients with T2DM not on an AHA or on any AHA in monotherapy or combination therapy (including oral or non oral agents)
* Patients with reduced kidney function

Exclusion Criteria:

* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
* Have proliferative diabetic retinopathy for which treatment is planned during the course of the study
* Kidney disease that required treatment with immunosuppressive therapy, history of dialysis or kidney transplant, presence of nephrotic syndrome (eg, severe proteinuria with hypoalbuminemia and/or edema), or inflammatory kidney disease
* Receiving anti hypertensive or anti-hyperlipidemic therapy not on a stable regimen
* History of a severe hypoglycemic episode within 6 months before screening

Primary outcomes:
measure: Change in HbA1c From Baseline to Week 26
timeFrame: Day 1 (Baseline) and Week 26
Secondary outcomes:
measure: Percentage of Patients With HbA1c <7% at Week 26
timeFrame: Week 26
measure: Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26
timeFrame: Day 1 (Baseline) and Week 26
Other outcomes:
Locations:
city: Concord
country: United States
state: California
city: Fountain Valley
country: United States
state: California
city: San Diego
country: United States
state: California
city: Denver
country: United States
state: Colorado
city: Pembroke Pines
country: United States
state: Florida
city: Tampa
country: United States
state: Florida
city: West Palm Beach
country: United States
state: Florida
city: Augusta
country: United States
state: Georgia
city: Nampa
country: United States
state: Idaho
city: Baton Rouge
country: United States
state: Louisiana
city: Jackson
country: United States
state: Mississippi
city: Picayune
country: United States
state: Mississippi
city: Chesterfield
country: United States
state: Missouri
city: Las Vegas
country: United States
state: Nevada
city: Albuquerque
country: United States
state: New Mexico
city: Durham
country: United States
state: North Carolina
city: Canal Fulton
country: United States
state: Ohio
city: Cincinnati
country: United States
state: Ohio
city: Columbus
country: United States
state: Ohio
city: Zanesville
country: United States
state: Ohio
city: Oklahoma City
country: United States
state: Oklahoma
city: Meridian
country: United States
state: Pennsylvania
city: Pittsburgh
country: United States
state: Pennsylvania
city: North Charleston
country: United States
state: South Carolina
city: Salt Lake City
country: United States
state: Utah
city: Fairfax
country: United States
state: Virginia
city: Camperdown
country: Australia
city: Gosford
country: Australia
city: Parkville
country: Australia
city: Reservoir
country: Australia
city: Aalst
country: Belgium
city: Bonheiden
country: Belgium
city: Brussels
country: Belgium
city: Liège
country: Belgium
city: Sint-Niklaas
country: Belgium
city: Turnhout
country: Belgium
city: Sao Paulo
country: Brazil
city: São Paulo
country: Brazil
city: Vancouver
country: Canada
state: British Columbia
city: Victoria
country: Canada
state: British Columbia
city: Antigonish
country: Canada
state: Nova Scotia
city: Sydney
country: Canada
state: Nova Scotia
city: Hamilton
country: Canada
state: Ontario
city: London
country: Canada
state: Ontario
city: Smiths Falls
country: Canada
state: Ontario
city: Thornhill
country: Canada
state: Ontario
city: Montreal
country: Canada
state: Quebec
city: Calgary
country: Canada
city: Corbeil Essonnes
country: France
city: La Rochelle Cedex 1 Poitou-Cha
country: France
city: Le Creusot
country: France
city: Nantes N/A
country: France
city: Pierre Benite
country: France
city: Vandoeuvre Les Nancy
country: France
city: Venissieux
country: France
city: Dormagen
country: Germany
city: Dortmund
country: Germany
city: Dresden
country: Germany
city: Einbeck
country: Germany
city: Freiburg
country: Germany
city: Kassel
country: Germany
city: München
country: Germany
city: Schkeuditz
country: Germany
city: Würzburg
country: Germany
city: Aurangabad
country: India
city: Madurai
country: India
city: Pune
country: India
city: Seognam-Si, Kyungki-Do
country: Korea, Republic of
city: Seoul
country: Korea, Republic of
city: Daugavpils
country: Latvia
city: Ogre
country: Latvia
city: Riga
country: Latvia
city: Jalan Cheras N/A
country: Malaysia
city: Kajang
country: Malaysia
city: Kuala Lumpur N/A
country: Malaysia
city: Pulau Pinang
country: Malaysia
city: Aguascalientes
country: Mexico
city: Culiacan
country: Mexico
city: Morelia
country: Mexico
city: Zapopan
country: Mexico
city: Auckland
country: New Zealand
city: Christchurch
country: New Zealand
city: Dunedin Nz
country: New Zealand
city: Nz
country: New Zealand
city: Lask
country: Poland
city: Lublin
country: Poland
city: Warszawa
country: Poland
city: Bucharest
country: Romania
city: Targoviste
country: Romania
city: Chelyabinsk
country: Russian Federation
city: Kirov
country: Russian Federation
city: Kursk
country: Russian Federation
city: Moscow
country: Russian Federation
city: Nizhny Novgorod
country: Russian Federation
city: Petrozavodsk
country: Russian Federation
city: Rostov-On-Don
country: Russian Federation
city: Saint Petersburg
country: Russian Federation
city: St Petersburg
country: Russian Federation
city: Yaroslavl
country: Russian Federation
city: Parow, Cape Town
country: South Africa
city: Pretoria
country: South Africa
city: Somerset West
country: South Africa
city: Barcelona
country: Spain
city: Ciudad Real
country: Spain
city: Madrid N/A
country: Spain
city: Madrid
country: Spain
city: San Sebastian De Los Reyes
country: Spain
city: Santa Cruz De Tenerife
country: Spain
city: Valencia
country: Spain
Study officials:
affiliation: Janssen Research & Development, LLC
name: Janssen Research & Development, LLC C. Clinical Trial
role: STUDY_DIRECTOR
References:
citation: Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016 Jan;101(1):157-66. doi: 10.1210/jc.2015-3167. Epub 2015 Nov 18.
citation: Weir MR, Kline I, Xie J, Edwards R, Usiskin K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014 Sep;30(9):1759-68. doi: 10.1185/03007995.2014.919907. Epub 2014 May 22.
citation: Nyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K, Usiskin K. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014 Jun;30(6):1109-19. doi: 10.1185/03007995.2014.890925. Epub 2014 Feb 21.